Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Ginger and Gut Microbiome (GINGER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03268655
Recruitment Status : Completed
First Posted : August 31, 2017
Last Update Posted : July 22, 2020
Information provided by (Responsible Party):
University of Minnesota

Brief Summary:
Estimate the impact of a 6-week daily intake of 2000 mg of ginger extract on the composition of the gut microbiome using a randomized placebo-controlled double-blinded design, i.e. examine the change of microbiome over time within and between the subjects..

Condition or disease Intervention/treatment Phase
Colorectal Adenoma Dietary Supplement: Ginger extract Other: Placebo Not Applicable

Detailed Description:

This is a pilot trial to evaluate the feasibility of conducting a large randomized trial and estimate the effects of ginger extract on the gut microbiome. The pilot study will recruit from multiple sites 95-100 subjects aged 50-75 years old who were diagnosed with colorectal adenoma within the last five years. There will be 47-50 subjects in the treatment group and 47-50 in the placebo group. The subjects will be randomized to receive either 2000 mg of ginger extract per day (1000 mg twice a day) or matching placebo.

Subjects will provide three stool specimens for analysis of the intestinal microbiome over a 12-week period at the following intervals: Week 0 (Day 1), Week 6, and Week 12. Although the gut microbiome is stable within a period of 1-2 months, a control arm will be included to account for potential dietary and other changes that may affect the gut microbiome. Gut microbiome composition - the presence, abundance, and diversity of bacterial taxa - will be derived by sequencing microbial 16S ribosomal RNA genes.

Primary Aims:

Aim 1 is to estimate the impact of a 6-week daily intake of 2000 mg of ginger extract on the composition of the gut microbiome using a randomized placebo-controlled double-blinded design, i.e. examine the change of microbiome over time within and between the subjects.

Aim 2 will examine the correlation between the ginger-related changes in microbiome profile with the levels of circulating biomarkers: urinary Prostaglandin E (PGE) metabolites.

Hypothesis: In the ginger versus placebo arm, gut microbiome will shift towards a lower proportion of pro-inflammatory, bacteria associated with colorectal cancer (CRC) and higher proportion of anti-inflammatory, CRC-protective bacteria.

Secondary Aim:

  1. At the end of the study, we expect to show that ginger decreases the relative abundance of pro-inflammatory, CRC-predisposing taxa and increases the abundance of anti-inflammatory, CRC-protective taxa, i.e., demonstrate that ginger boosts changes in gut microbiome that are protective against CRC, as well as assess ginger-induced changes in immune response.
  2. The similarities of bacterial profiles will be compared between three time points baseline and 6 Weeks and 12 Weeks to estimate whether 6-week is a sufficient time for washout.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 68 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Pilot. Double-blind placebo-controlled randomized trial
Masking: Double (Participant, Investigator)
Masking Description: Double blind
Primary Purpose: Basic Science
Official Title: Pilot Trial to Examine the Effect of Ginger on the Gut Microbiome (GINGER)
Actual Study Start Date : November 14, 2018
Actual Primary Completion Date : June 26, 2020
Actual Study Completion Date : June 26, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Ginger extract
Ginger extract, 2000 mg daily for 6 weeks, followed by 6 week washout.
Dietary Supplement: Ginger extract
2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout

Experimental: Placebo
Placebo, daily for 6 weeks, followed by 6 week washout.
Other: Placebo
2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout

Primary Outcome Measures :
  1. Composition of the gut microbiome [ Time Frame: Baseline to 6 Weeks ]
    Fecal microbial diversity and the prevalence of specific taxa associated with colorectal cancer (e.g. Fusobacteria, butyrate producing bacteria) will be estimated at 6 weeks. The ginger-related changes in the prevalence of each taxon will be assessed individually and also combined into a microbiome index (the abundance of protective taxa will be included as a negative value).

  2. Urine inflammatory biomarker [ Time Frame: Baseline to 6 weeks ]
    Urinary metabolite of Prostaglandin E2 (ng/mg of creatinine) will be measured before and after treatment with ginger. Changes in inflammatory markers will be correlated to changes in the microbial diversity and the microbiome composition

Secondary Outcome Measures :
  1. Change in gut microbiome composition [ Time Frame: Baseline to 12 weeks ]
    Beta-diversity will be compared between three time points: baseline, 6 Weeks and 12 Weeks.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Colorectal adenoma diagnosis

Exclusion Criteria:

  • Allergy or sensitivity to ginger
  • Active cancer
  • Unstable medical condition
  • Unstable diet or weight

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03268655

Layout table for location information
United States, Minnesota
Mayo Clinic Cancer Center
Albert Lea, Minnesota, United States, 56007
Mayo Clinic Cancer Center
Austin, Minnesota, United States, 55912
Essentia Health - Deer River
Deer River, Minnesota, United States, 56636
Essentia Health St Mary's - Detroit Lakes
Detroit Lakes, Minnesota, United States, 56501
Essentia Health - Fosston Clinic
Fosston, Minnesota, United States, 56542
Fairview Grand Itasca Clinic & Hospital
Grand Rapids, Minnesota, United States, 55744
Fairview Range Medical Center
Hibbing, Minnesota, United States, 55746
Mayo Clinic Cancer System
Mankato, Minnesota, United States, 56001
Epidemiology Clinical Research Center
Minneapolis, Minnesota, United States, 55415
Monticello Cancer Center
Monticello, Minnesota, United States, 55362
Essentia Health - Park Rapids Clinic
Park Rapids, Minnesota, United States, 56470
Fairview Northland Medical Center
Princeton, Minnesota, United States, 55371
Essentia Health -Virgina Clinic
Virginia, Minnesota, United States, 55792
Sponsors and Collaborators
University of Minnesota
Layout table for investigator information
Principal Investigator: Anna Prizment, PhD, MPH University of Minnesota, Epidemiology and Community Health
Layout table for additonal information
Responsible Party: University of Minnesota Identifier: NCT03268655    
Other Study ID Numbers: SPH-2017-25928
Anna-CPRC-TBD ( Other Identifier: UMN Clinical Protocol Review Committee )
First Posted: August 31, 2017    Key Record Dates
Last Update Posted: July 22, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: The results of the study will be disseminated to various stakeholders through the publication of a manuscript in a peer-reviewed journal and through presentation at scientific meetings.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Minnesota:
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type